uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Viral safety of human platelet lysate for cell therapy and regenerative medicine: Moving forward, yes, but without forgetting the past
Taipei Med Univ, Coll Biomed Engn, Grad Inst Biomed Mat & Tissue Engn, Taipei, Taiwan;Taipei Med Univ, Coll Biomed Engn, Int PhD Program Biomed Engn, Taipei, Taiwan;Taipei Med Univ, Coll Biomed Engn, Res Ctr Biomed Devices, Taipei, Taiwan;Taipei Med Univ, Coll Med, Int PhD Program Cell Therapy & Regenerat Med, Taipei, Taiwan.
Taipei Med Univ, Coll Biomed Engn, Int PhD Program Biomed Engn, Taipei, Taiwan.
Taipei Med Univ, Coll Biomed Engn, Grad Inst Biomed Mat & Tissue Engn, Taipei, Taiwan.
Taipei Med Univ, Coll Biomed Engn, Grad Inst Biomed Mat & Tissue Engn, Taipei, Taiwan.
Show others and affiliations
2019 (English)In: Transfusion and apheresis science, ISSN 1473-0502, E-ISSN 1878-1683, Vol. 58, no 6, article id 102674Article, review/survey (Refereed) Published
Abstract [en]

Growth factor-rich pooled human platelet lysate (HPL), made from human platelet concentrates, is one new blood-derived bioproduct that is attracting justified interest as a xeno-free supplement of growth media for human cell propagation for cell therapy. HPL can also find potentially relevant applications in the field of regenerative medicine. Therefore, the therapeutic applications of HPL go far beyond the standard clinical applications of the traditional blood products typically used in patients suffering from life-threatening congenital or acquired deficiencies in cellular components or proteins due to severe genetic diseases or trauma. A wider population of patients, suffering from various pathologies than has traditionally been the case, is thus, now susceptible to receiving a human blood-derived product. These patients would, therefore, be exposed to the possible, but avoidable, side effects of blood products, including transfusion-transmitted infections, most specifically virus transmissions. Unfortunately, not all manufacturers, suppliers, and users of HPL may have a strong background in the blood product industry. As such, they may not be fully aware of the various building blocks that should contribute to the viral safety of HPL as is already the case for any licensed blood products. The purpose of this manuscript is to reemphasize all the measures, including in regulatory aspects, capable of assuring that HPL exhibits a sufficient pathogen safety margin, especially when made from large pools of human platelet concentrates. It is vital to remember the past to avoid that the mistakes, which happened 30 to 40 years ago and led to the contamination of many blood recipients, be repeated due to negligence or ignorance of the facts.

Place, publisher, year, edition, pages
PERGAMON-ELSEVIER SCIENCE LTD , 2019. Vol. 58, no 6, article id 102674
Keywords [en]
Human platelet lysate, Virus, Safety, HPL
National Category
Hematology
Identifiers
URN: urn:nbn:se:uu:diva-403038DOI: 10.1016/j.transci.2019.102674ISI: 000505103700021PubMedID: 31735652OAI: oai:DiVA.org:uu-403038DiVA, id: diva2:1387854
Available from: 2020-01-22 Created: 2020-01-22 Last updated: 2020-01-22Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Knutson, Folke

Search in DiVA

By author/editor
Knutson, Folke
By organisation
Clinical Immunology
In the same journal
Transfusion and apheresis science
Hematology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 4 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf